Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.48 |
| ▸ | CCND1 | P24385 | 6/20 | 0.48 |
| ▸ | CCND3 | P30281 | 5/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075581 | 0.91 | CDK4 (0.49) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL111630 | 0.88 | CDK4 (0.56) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL112881 | 0.76 | CDK4 (0.74) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL112592 | 0.74 | CDK4 (0.63) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL113181 | 0.73 | CDK4 (0.66) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL2142406 | 0.73 | CDK4 (0.78) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL2128517 | 0.73 | CDK4 (0.59) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL2143684 | 0.73 | CDK4 (0.65) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL2143680 | 0.73 | CDK4 (0.65) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL13076190 | 0.72 | CDK4 (0.51) | CDK4CCND1CCND3CDK6CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | CDK4 13/4885CCND1 30/4885CCND3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.